Compare Berkshire Hathaway Inc Class B (BRK.B) vs Hims and Hers Health Inc (HIMS) Price & Performance

BRK.B trades at $529.65, up 1.73% today, with a bullish technical signal from moving averages and oscillators. The stock is near its pivot point of $530, with support at $522 and resistance at $536. Analyst consensus is positive, with 57% of 7 analysts rating it a Buy and none recommending Sell, indicating strong institutional confidence.

The outlook remains favorable given the bullish technicals and analyst support, though overbought RSI readings suggest near-term caution. Key risks include market volatility and macroeconomic pressures, but the stock's strong fundamentals and institutional backing provide a solid foundation for potential growth.

HIMS stock declined 7.11% to $29.51 following mixed Q2 2026 results, where revenue beat expectations but the company posted a wider-than-expected loss. The technical picture is neutral with bearish moving average signals, while fundamentals show strong revenue growth but deteriorating margins. Recent news highlights margin pressure from GLP-1 drug investments and an FTC investigation, creating investor uncertainty despite raised revenue guidance.

The outlook remains cautious as strong subscriber growth and AI initiatives are offset by profitability challenges and regulatory scrutiny. Investment opportunity exists in the company's expanding global footprint and raised revenue targets, but risks include margin compression, negative cash flow trends, and ongoing legal investigations that could pressure the stock near-term.